These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 28323985

  • 1. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
    Kornaczewski Jackson ER, Pointon OP, Bohmer R, Burgess JR.
    J Clin Endocrinol Metab; 2017 Jun 01; 102(6):1926-1933. PubMed ID: 28323985
    [Abstract] [Full Text] [Related]

  • 2. 18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.
    Satoh K, Sadowski SM, Dieckmann W, Quezado M, Nilubol N, Kebebew E, Patel D.
    Ann Surg Oncol; 2016 Dec 01; 23(Suppl 5):714-721. PubMed ID: 27638678
    [Abstract] [Full Text] [Related]

  • 3. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
    van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, Koopmans KP, Valk GD, Timmers HJ, de Herder WW, Feelders RA, Fockens P, Sluiter WJ, de Vries EG, Links TP.
    Gastrointest Endosc; 2015 Jan 01; 81(1):159-167.e2. PubMed ID: 25527055
    [Abstract] [Full Text] [Related]

  • 4. An assessment of 18 F-FDG PET/CT for thoracic screening and risk stratification of pulmonary nodules in multiple endocrine neoplasia type 1.
    So A, Pointon O, Hodgson R, Burgess J.
    Clin Endocrinol (Oxf); 2018 May 01; 88(5):683-691. PubMed ID: 29446832
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with pancreatic neuroendocrine tumors.
    Matsumoto T, Okabe H, Yamashita YI, Yusa T, Itoyama R, Nakao Y, Yamao T, Umzaki N, Tsukamoto M, Kitano Y, Miyata T, Arima K, Nitta H, Hayashi H, Imai K, Chikamoto A, Baba H.
    Surg Today; 2019 Jan 01; 49(1):21-26. PubMed ID: 30128759
    [Abstract] [Full Text] [Related]

  • 7. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (18 F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors.
    Lung MS, Hicks RJ, Pavlakis N, Link E, Jefford M, Thomson B, Wyld DK, Liauw W, Akhurst T, Kuru N, Michael M.
    Asia Pac J Clin Oncol; 2020 Jun 01; 16(3):150-157. PubMed ID: 32030887
    [Abstract] [Full Text] [Related]

  • 8. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A, Modica R, Lo Calzo F, Camera L, Napolitano V, Altieri B, de Cicco F, Bottiglieri F, Sesti F, Badalamenti G, Isidori AM, Colao A.
    J Clin Endocrinol Metab; 2020 Jan 01; 105(1):. PubMed ID: 31586182
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
    Jullien M, Reichert T, D'Anella P, Castinetti F, Barlier A, Brue T, Taieb D, Cuny T.
    Ann Endocrinol (Paris); 2020 Feb 01; 81(1):39-43. PubMed ID: 31982106
    [Abstract] [Full Text] [Related]

  • 10. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y, Eguchi H, Tatsumi M, Kim T, Hama N, Wada H, Kawamoto K, Kobayashi S, Morii E, Mori M, Doki Y, Nagano H.
    Surgery; 2015 Feb 01; 157(2):269-76. PubMed ID: 25311263
    [Abstract] [Full Text] [Related]

  • 11. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
    Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E.
    Surgery; 2011 Dec 01; 150(6):1122-8. PubMed ID: 22136831
    [Abstract] [Full Text] [Related]

  • 12. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
    Challis BG, Casey RT, Grossman A, Newell-Price J, Newey P, Thakker RV.
    Clin Endocrinol (Oxf); 2019 Dec 01; 91(6):708-715. PubMed ID: 31505044
    [Abstract] [Full Text] [Related]

  • 13. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
    Sadowski SM, Weisbrod AB, Ellis R, Patel D, Alimchandani M, Quezado M, Millo C, Venzon DJ, Nilubol N, Linehan WM, Kebebew E.
    J Am Coll Surg; 2014 May 01; 218(5):997-1003. PubMed ID: 24661849
    [Abstract] [Full Text] [Related]

  • 14. Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study.
    Kappelle WF, Valk GD, Leenders M, Moons LM, Bogte A, Siersema PD, Vleggaar FP.
    Endoscopy; 2017 Jan 01; 49(1):27-34. PubMed ID: 27975336
    [Abstract] [Full Text] [Related]

  • 15. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.
    Sampathirao N, Basu S.
    J Nucl Med Technol; 2017 Mar 01; 45(1):34-41. PubMed ID: 28154019
    [Abstract] [Full Text] [Related]

  • 16. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
    Kornaczewski ER, Pointon OP, Burgess JR.
    Clin Endocrinol (Oxf); 2016 Aug 01; 85(2):172-9. PubMed ID: 26776272
    [Abstract] [Full Text] [Related]

  • 17. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW, Xu BX, Wang RM, Sun L, Tian JH.
    Hell J Nucl Med; 2013 Aug 01; 16(2):97-102. PubMed ID: 23687644
    [Abstract] [Full Text] [Related]

  • 18. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
    Chiloiro S, Lanza F, Bianchi A, Schinzari G, Brizi MG, Giampietro A, Rufini V, Inzani F, Giordano A, Rindi G, Pontecorvi A, De Marinis L.
    Endocrine; 2018 May 01; 60(2):362-367. PubMed ID: 28567607
    [Abstract] [Full Text] [Related]

  • 19. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J, Gan G, Farlow D, Laurence JM, Hollands M, Richardson A, Pleass HC, Lam VW.
    ANZ J Surg; 2012 Mar 01; 82(3):140-4. PubMed ID: 22510123
    [Abstract] [Full Text] [Related]

  • 20. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
    Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De Luca L, Fonti R, Napolitano V, Colao A.
    Endocrine; 2016 Jun 01; 52(3):488-94. PubMed ID: 26242621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.